356
Participants
Start Date
May 31, 2002
Primary Completion Date
May 31, 2005
Study Completion Date
March 31, 2011
MRI/MRS
Serial MRI studies evaluated for prognostic properties related to therapeutic response.
gadopentetate dimeglumine
Imaging agent used for contrast enhancement in each of the MRIs.
Memorial Sloan-Kettering Cancer Center, New York
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington D.C.
UAB Comprehensive Cancer Center, Birmingham
Masonic Cancer Center at University of Minnesota, Minneapolis
Mayo Clinic Cancer Research Consortium, Rochester
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
University of Chicago Cancer Research Center, Chicago
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas
National Cancer Institute (NCI)
NIH
American College of Radiology Imaging Network
NETWORK